Zhi Tong Cai Jing·2025-09-02 08:56Group 1 - The core viewpoint of the report is that China Resources Pharmaceutical (3320) is maintained with a "buy" rating, with expectations of a valuation reassessment opportunity in fiscal year 2026 and beyond [1] - The target price has been adjusted from HKD 8.1 to HKD 5.9, corresponding to price-to-earnings ratios of 9 times for 2026 and 8 times for 2027 [1] - The company's performance is in line with expectations, showing overall stability with a revenue of RMB 131.867 billion, a year-on-year increase of 2.5% [1] Group 2 - The net profit for the company was RMB 2.077 billion, reflecting a year-on-year decline of 20.3% [1] - The overall gross margin remained stable at 16.3%, with a selling expense ratio of 7.6% and a management expense ratio of 2.4% [1] - Research and development investment reached RMB 1.25 billion, indicating a commitment to innovation despite the profit decline [1]